In a patient with a serum sodium of 124 mEq/L, can we start a 3 % NaCl infusion concurrently with terlipressin?

Can 3% NaCl Be Started Alongside Terlipressin?

No, you should not routinely start 3% hypertonic saline concurrently with terlipressin in a patient with serum sodium of 124 mEq/L, as terlipressin itself frequently causes significant hyponatremia and the combination creates an unpredictable sodium trajectory with high risk of dangerous overcorrection. 1

The Core Problem: Terlipressin Causes Hyponatremia

Terlipressin, despite being primarily a V1 receptor agonist, has partial V2 receptor activity that commonly induces hyponatremia:

• 67% of patients develop a decrease in serum sodium ≥5 mEq/L during terlipressin therapy
• 36% experience drops >10 mEq/L, with sodium falling from baseline ~137 to ~120 mEq/L 2
• 68.9% of elderly cirrhotic patients developed hyponatremia, with 37.8% reaching moderate-to-severe levels (Na <130 mEq/L) 3
• The sodium drop occurs rapidly after starting therapy and is usually reversible after terlipressin withdrawal 2, 4

Risk Factors for Terlipressin-Induced Hyponatremia

Patients at highest risk include those with:

• Normal or near-normal baseline sodium (paradoxically at higher risk) 2
• Lower MELD scores 2
• Child-Pugh class C (OR 3.12) 3
• Already reduced baseline sodium (per 5 mEq/L decrease, OR 2.05) 3

Your patient with Na 124 mEq/L has two of these risk factors (reduced baseline sodium and likely advanced liver disease).

The Danger of Concurrent Administration

Unpredictable Sodium Trajectory

When you combine 3% saline (which raises sodium) with terlipressin (which lowers sodium), you create competing forces with unpredictable net effects:

1. Initial phase: 3% saline may raise sodium while terlipressin's hyponatremic effect develops
2. During terlipressin therapy: The sodium-lowering effect may counteract or overwhelm the saline
3. After stopping terlipressin: Rapid rebound increase in sodium if saline continues

Osmotic Demyelination Risk

The most critical danger is osmotic demyelination syndrome (ODS), which occurs with:

• Rapid correction >10-12 mEq/L in 24 hours 5
• Correction >8 mEq/L in 24 hours in high-risk patients (advanced liver disease, malnutrition, hypokalemia) 5

Three patients developed neurological manifestations from terlipressin-induced hyponatremia, including one case of ODS due to rapid sodium recovery after drug withdrawal 2. If you're simultaneously giving 3% saline when terlipressin is stopped, the risk of dangerous overcorrection multiplies.

Guideline-Based Management Strategy

For Your Patient (Na 124 mEq/L)

Step 1: Determine if this is symptomatic or severe hyponatremia

• Symptomatic (confusion, seizures, altered mental status) or Na <120 mEq/L = severe 1
• Your patient at 124 mEq/L is moderate hyponatremia (120-125 mEq/L) 5

Step 2: If starting terlipressin for HRS-AKI:

The FDA label and clinical trials show that albumin is the standard volume expander used with terlipressin, not hypertonic saline 6:

• Albumin 1 g/kg on day 1 (max 100g)
• Then 20-40 g/day as clinically indicated
• Median dose in trials: 50 g/day 6

Step 3: Manage the moderate hyponatremia conservatively:

• Water restriction to 1000 mL/day 5
• Discontinue or reduce diuretics 1, 5
• Correct hypokalemia 1
• Albumin infusion (which you're already giving for HRS-AKI) 1

Step 4: Reserve 3% saline for specific scenarios ONLY:

• Life-threatening hyponatremia (severe symptoms, Na <120 mEq/L) 1
• Imminent liver transplantation requiring pre-operative correction 5
• Short-term use only 5

If 3% Saline Is Absolutely Required

If the patient has severe symptomatic hyponatremia requiring emergent treatment:

1. Use 3% saline BEFORE starting terlipressin, not concurrently
2. Target correction rate: 4-6 mEq/L per 24 hours, not exceeding 8 mEq/L in high-risk cirrhotic patients 5
3. Stop 3% saline once symptoms resolve or Na reaches 120-125 mEq/L
4. Then start terlipressin with albumin
5. Monitor sodium every 4-6 hours during terlipressin therapy 2, 4

Monitoring Protocol During Terlipressin

Intensive sodium monitoring is mandatory:

• Check sodium every 4-6 hours initially 4
• Watch for rapid drops (can occur within 72 hours) 4
• If sodium drops >10 mEq/L or becomes <120 mEq/L, consider holding terlipressin 2
• After stopping terlipressin, continue monitoring for rapid rebound 2, 4

Key Pitfalls to Avoid

1. Don't assume terlipressin won't affect sodium - it's a common and potentially severe complication
2. Don't use 3% saline as routine volume expansion - albumin is the evidence-based choice with terlipressin 6
3. Don't continue 3% saline when stopping terlipressin - this creates high overcorrection risk
4. Don't neglect sodium monitoring - check frequently, especially in first 72 hours
5. Don't forget that Child-Pugh C patients are at highest risk for both terlipressin-induced hyponatremia and ODS 3, 5

Alternative Consideration

If hyponatremia correction is the primary goal rather than HRS-AKI treatment, terlipressin has actually been studied as a treatment FOR hyponatremia in liver failure, with improved transplant-free survival 7. This paradoxical use exploits its splanchnic vasoconstriction to improve effective arterial volume, but requires careful patient selection and monitoring.

Bottom line: Use albumin as your volume expander with terlipressin, manage moderate hyponatremia conservatively with fluid restriction, and reserve 3% saline for life-threatening situations only—never as routine concurrent therapy.